mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Aug. 31, 2024

Abstract Malignant tumors remain a primary cause of human mortality. Among the various treatment modalities for neoplasms, tumor vaccines have consistently shown efficacy and promising potential. These offer advantages such as specificity, safety, tolerability, with mRNA representing platforms. By introducing exogenous mRNAs encoding antigens into somatic cells subsequently synthesizing through gene expression systems, can effectively induce immune responses. Katalin Karikó Drew Weissman were awarded 2023 Nobel Prize in Physiology or Medicine their great contributions to vaccine research. Compared traditional vaccines, several advantages, including rapid preparation, reduced contamination, nonintegrability, high biodegradability. Tumor-targeted therapy is an innovative modality that enables precise targeting cells, minimizes damage normal tissues, safe at doses, demonstrates efficacy. Currently, targeted has become important option malignant tumors. The application tumor-targeted expanding, numerous clinical trials underway. We systematically outline delivery mechanism by which anti-tumor responses, describe current research applications therapy, forecast future development trends therapy.

Language: Английский

Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 5, 2024

This study examines the humoral and cellular response in multiple sclerosis (MS) patients on anti-CD20 therapy before after 1st to 4th BNT162b2 mRNA SARS-CoV-2 vaccination relationship with breakthrough infection.

Language: Английский